CRISPR Therapeutics Stock Forecast, Price & News

CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics or view top-rated stocks.

How has CRISPR Therapeutics' stock been impacted by Coronavirus?

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRSP stock has increased by 82.0% and is now trading at $78.79.
View which stocks have been most impacted by COVID-19.

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 5,580,000 shares, an increase of 15.8% from the October 14th total of 4,820,000 shares. Based on an average trading volume of 1,260,000 shares, the short-interest ratio is presently 4.4 days. Approximately 8.0% of the company's shares are short sold.
View CRISPR Therapeutics' Short Interest.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for CRISPR Therapeutics.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($1.67) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.75) by $0.08. CRISPR Therapeutics had a net margin of 45.64% and a trailing twelve-month return on equity of 19.19%.
View CRISPR Therapeutics' earnings history.

What price target have analysts set for CRSP?

16 analysts have issued 12 month price targets for CRISPR Therapeutics' shares. Their forecasts range from $101.00 to $210.00. On average, they anticipate CRISPR Therapeutics' stock price to reach $160.40 in the next year. This suggests a possible upside of 103.6% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics or view top-rated stocks among Wall Street analysts.

What are Wall Street analysts saying about CRISPR Therapeutics stock?

Here are some recent quotes from research analysts about CRISPR Therapeutics stock:

• 1. SVB Leerink LLC analysts commented, " (10/19/2021)
• 2. According to Zacks Investment Research, "CRISPR Therapeutics' lead pipeline candidate CTX001, a CRISPR gene-edited therapy, is being developed for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in collaboration with Vertex. If successfully developed, CTX001 can reap huge profits as both diseases have a high unmet medical need. The company’s other pipeline candidates are in early-stage development for various cancer indications. However, in absence of a marketed product, it is solely dependent on Vertex for collaborations revenues, which remains a constant woe. Moreover, its candidates are years away from achieving commercialization. Acute competition is also a worry for CRISPR Therapeutics as some companies are developing gene-edited therapies. Shares of the company have outperformed the industry year to date." (2/1/2021)

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:

• Rodger Novak, Chairman & President
• Samarth Kulkarni, Chief Executive Officer & Director (LinkedIn Profile)
• Lawrence O. Klein, Chief Operating Officer
• Brendan Smith, Senior VP, Chief Financial & Accounting Officer
• Tony W. Ho, Executive VP, Head-Research & Development

Who are some of CRISPR Therapeutics' key competitors?

Some companies that are related to CRISPR Therapeutics include Bio-Techne (TECH), Novozymes A/S (NVZMY), Novavax (NVAX), Repligen (RGEN), argenx (ARGX), QIAGEN (QGEN), Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Exelixis (EXEL), Beam Therapeutics (BEAM), Abcam (ABCM), Fate Therapeutics (FATE), Kodiak Sciences (KOD) and Halozyme Therapeutics (HALO).
View all of CRSP's competitors.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (4.30%), BlackRock Inc. (1.48%), Macquarie Group Ltd. (1.29%), Bellevue Group AG (1.27%), Morgan Stanley (0.76%) and Versant Venture Management LLC (0.65%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics.

Which institutional investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Two Sigma Investments LP, Clough Capital Partners L P, Macquarie Group Ltd., Jane Street Group LLC, First Republic Investment Management Inc., Nikko Asset Management Americas Inc., and Citadel Advisors LLC. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for CRISPR Therapeutics or view top insider-selling stocks.

Which institutional investors are buying CRISPR Therapeutics stock?

CRSP stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Goldman Sachs Group Inc., SG Americas Securities LLC, Nordea Investment Management AB, Jennison Associates LLC, BlackRock Inc., Wilbanks Smith & Thomas Asset Management LLC, and Morgan Stanley.
View insider buying and selling activity for CRISPR Therapeutics or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $78.79.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $6.03 billion and generates $720 thousand in revenue each year. The company earns $-348.86 million in net income (profit) each year or $4.76 on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 410 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

Where are CRISPR Therapeutics' headquarters?

CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].